Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Sacramento, CA
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
San Francisco, CA
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
San Ramon, CA
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
San Ramon, CA
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Santa Monica, CA
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Denver, CO
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Farmington, CT
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Farmington, CT
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Jacksonville, FL
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Miami, FL
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Tampa, FL
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Tampa, FL
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Atlanta, GA
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Macon, GA
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Macon, GA
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Skokie, IL
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Skokie, IL
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
New Albany, IN
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
New Albany, IN
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Plainfield, IN
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Plainfield, IN
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Louisville, KY
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
New Orleans, LA
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Boston, MA
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Omaha, NE
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
East Windsor, NJ
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
East Windsor, NJ
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Verona, NJ
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Verona, NJ
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Rochester, NY
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Plymouth Meeting, PA
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Plymouth Meeting, PA
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Johnston, RI
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Johnston, RI
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Charleston, SC
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Bartlett, TN
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Bartlett, TN
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Knoxville, TN
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Nashville, TN
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Dallas, TX
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Houston, TX
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Norfolk, VA
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Walla Walla, WA
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Walla Walla, WA
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
mi
from
Winnipeg,
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
mi
from
Winnipeg,
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Saint Petersburg, FL
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/8/2017
Novartis Investigator Site
mi
from
Birmingham, AL
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/8/2017
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/8/2017
Novartis Investigative Site
mi
from
Little Rock, AR
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/8/2017
Novartis Investigative Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/8/2017
Novartis Investigative Site
mi
from
Pasadena, CA
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/8/2017
Novartis Investigative Site
mi
from
Pasadena, CA
Click here to add this to my saved trials
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/8/2017
Novartis Investigative Site
mi
from
San Diego, CA
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/8/2017
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/8/2017
Novartis Investigative Site
mi
from
Newnan, GA
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/8/2017
Novartis Investigative Site
mi
from
Newnan, GA
Click here to add this to my saved trials
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/8/2017
Novartis Investigative Site
mi
from
Snellville, GA
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/8/2017
Novartis Investigative Site
mi
from
Snellville, GA
Click here to add this to my saved trials
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/8/2017
Novartis Investigative Site
mi
from
Champaign, IL
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/8/2017
Novartis Investigative Site
mi
from
Champaign, IL
Click here to add this to my saved trials
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/8/2017
Novartis Investigational Site
mi
from
Springfield, IL
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/8/2017
Novartis Investigational Site
mi
from
Springfield, IL
Click here to add this to my saved trials
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/8/2017
Novartis Investigator Site
mi
from
Evansville, IN
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/8/2017
Novartis Investigator Site
mi
from
Evansville, IN
Click here to add this to my saved trials
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/8/2017
Novartis Investigator Site
mi
from
Topeka, KA
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/8/2017
Novartis Investigator Site
mi
from
Topeka, KA
Click here to add this to my saved trials
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/8/2017
Novartis Investigative Site
mi
from
Louisville, KY
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/8/2017
Novartis Investigative Site
mi
from
Louisville, KY
Click here to add this to my saved trials
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/8/2017
Novartis Investigative Site
mi
from
Detroit, MI
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/8/2017
Novartis Investigative Site
mi
from
Detroit, MI
Click here to add this to my saved trials
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/8/2017
Novartis Investigator Site
mi
from
Minneapolis, MN
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/8/2017
Novartis Investigator Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials